Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Combination Details

General Information of the Combination (ID: C97955)
Name Arsenic trioxide   NP Info  + Thalidomide   Drug Info 
Structure +
Disease
Multiple myeloma [ICD-11: 2A83]
Phase 2 [1]
Acute myeloid leukemia [ICD-11: 2A60]
Investigative [2]
Acute lymphoblastic leukemia [ICD-11: 2B33]
Investigative [3]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [3]
                    Molecule(s)
                    Regulation
Up-regulation Expression AKT1  Molecule Info 
Pathway MAP
Down-regulation Expression BECN1  Molecule Info 
Pathway MAP
Up-regulation Expression IL6  Molecule Info 
Pathway MAP
Up-regulation Expression MAP1LC3A  Molecule Info 
Pathway MAP
Up-regulation Expression MEK1  Molecule Info 
Pathway MAP
Up-regulation Expression mTOR  Molecule Info 
Pathway MAP
Up-regulation Expression PIK3CB  Molecule Info 
Pathway MAP
Up-regulation Expression PTEN  Molecule Info 
Pathway MAP
Up-regulation Expression SQSTM1  Molecule Info 
Pathway MAP
Down-regulation Expression ULK1  Molecule Info 
Pathway MAP
Up-regulation Expression VEGFC  Molecule Info 
Pathway MAP
                    In-vitro Model KG-1 CVCL_0374 Adult acute myeloid leukemia Homo sapiens
U-937 CVCL_0007 Adult acute monocytic leukemia Homo sapiens
                    Experimental
                    Result(s)
Arsenic trioxide and thalidomide combination induces autophagy along with apoptosis in acute myeloid cell lines.
                    Experiment 2 Reporting the Effect of This Combination [2]
                    Molecule(s)
                    Regulation
Down-regulation Expression VEGFA  Molecule Info 
Pathway MAP
                    In-vitro Model U-937 CVCL_0007 Adult acute monocytic leukemia Homo sapiens
KG-1 CVCL_0374 Adult acute myeloid leukemia Homo sapiens
                    Experimental
                    Result(s)
Arsenic trioxide and thalidomide combination showed inhibitory effects of on angiogenesis and vascular endothelial growth factor expression in leukemia cells.
References
Reference 1 ClinicalTrials.gov (NCT00193544) Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma.
Reference 2 Inhibitory Effects of Arsenic Trioxide and Thalidomide on Angiogenesis and Vascular Endothelial Growth Factor Expression in Leukemia Cells. Asian Pac J Cancer Prev. 2018 Apr 27;19(4):1127-1134.
Reference 3 Arsenic Trioxide and Thalidomide Combination Induces Autophagy Along with Apoptosis in Acute Myeloid Cell Lines. Cell J. 2020 Jul;22(2):193-202.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China